NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress

Current Cancer Drug Targets

Volumn 8, Issue 5, 2008, Pages 421-430

  Clark, David W ^a   Mitra, Aparna ^a   Fillmore, Rebecca A ^a   Jiang, Wen G ^b   Samant, Rajeev S ^a   Fodstad, Oystein ^a,c   Shevde, Lalita A ^a,d  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d USA Mitchell Cancer Institute   (United States)

Author keywords

Cell cycle; com1; Doxorubicin; NUPR1; p21; p53; p8; Taxol

Indexed keywords

CERAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; DOXORUBICIN; ESTROGEN RECEPTOR BETA; NUCLEAR PROTEIN; NUCLEAR PROTEIN 1; PACLITAXEL; PROTEIN BCL XL; PROTEIN P300; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMAD PROTEIN; STAUROSPORINE;

APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL GROWTH; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; EPITHELIUM CELL; GENOTOXICITY; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BCL-X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; E1A-ASSOCIATED P300 PROTEIN; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; NEOPLASM PROTEINS; PACLITAXEL; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-ABL; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48849090170     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785133196     Document Type: Article

References (51)

1. Mallo, G. V.; Fiedler, F.; Calvo, E. L.; Ortiz, E. M.; Vasseur, S.; Keim, V.; Morisset, J.; Iovanna, J. L. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J. Biol. Chem. 1997, 272, 32360-32369.
2. Encinar, J. A.; Mallo, G. V.; Mizyrycki, C.; Giono, L.; Gonzalez-Ros, J. M.; Rico, M.; Canepa, E.; Moreno, S.; Neira, J. L.; Iovanna, J. L. Human p8 is a HMG-I/Y-like protein with DNA binding activity enhanced by phosphorylation. J. Biol. Chem. 2001, 276, 2742-2751.
3. Hoffmeister, A.; Ropolo, A.; Vasseur, S.; Mallo, G. V.; Bodeker, H.; Ritz-Laser, B.; Dressler, G. R.; Vaccaro, M. I.; Dagorn, J. C.; Moreno, S.; Iovanna, J. L. The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. J. Biol. Chem. 2002, 277, 22314-22319.
4. Jiang, W. G.; Davies, G.; Fodstad, O. Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. Biochem. Biophys. Res. Commun. 2005, 330, 253-262.
5. Garcia-Montero, A. C.; Vasseur, S.; Giono, L. E.; Canepa, E.; Moreno, S.; Dagorn, J. C.; Iovanna, J. L. Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p8 gene expression. Biochem. J. 2001, 357, 249-253.
6. Malicet, C.; Giroux, V.; Vasseur, S.; Dagorn, J. C.; Neira, J. L.; Iovanna, J. L. Regulation of apoptosis by the p8/prothymosin alpha complex. Proc. Natl. Acad. Sci. USA 2006, 103, 2671-2676.
7. Taieb, D.; Malicet, C.; Garcia, S.; Rocchi, P.; Arnaud, C.; Dagorn, J. C.; Iovanna, J. L.; Vasseur, S. Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. Hepatology 2005, 42, 176-182.
8. Giroux, V.; Malicet, C.; Barthet, M.; Gironella, M.; Archange, C.; Dagorn, J. C.; Vasseur, S.; Iovanna, J. L. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin. Cancer Res. 2006, 12, 235-241.
9. Ree, A. H.; Pacheco, M. M.; Tvermyr, M.; Fodstad, O.; Brentani, M. M. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin. Cancer Res. 2000, 6, 1778-1783.
10. Ree, A. H.; Bratland, A.; Kroes, R. A.; Aasheim, H. C.; Florenes, V. A.; Moskal, J. R.; Fodstad, O.; Bruland, O. S.; Maelandsmo, G. M. Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res. 2002, 22, 1949-1957.
11. Vasseur, S.; Mallo, G. V.; Garcia-Montero, A.; Ortiz, E. M.; Fiedler, F.; Canepa, E.; Moreno, S.; Iovanna, J. L. Structural and functional characterization of the mouse p8 gene: promotion of transcription by the CAAT-enhancer binding protein alpha (C/EBPalpha) and C/EBPbeta trans-acting factors involves a C/EBP cis-acting element and other regions of the promoter. Biochem. J. 1999, 343(Pt 2), 377-383.
12. Su, S. B.; Motoo, Y.; Iovanna, J. L.; Berthezene, P.; Xie, M. J.; Mouri, H.; Ohtsubo, K.; Matsubara, F.; Sawabu, N. Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clin. Cancer Res. 2001, 7, 1320-1324.
13. Su, S. B.; Motoo, Y.; Iovanna, J. L.; Xie, M. J.; Mouri, H.; Ohtsubo, K.; Yamaguchi, Y.; Watanabe, H.; Okai, T.; Matsubara, F.; Sawabu, N. Expression of p8 in human pancreatic cancer. Clin. Cancer Res. 2001, 7, 309-313.
14. Vasseur, S.; Hoffmeister, A.; Garcia, S.; Bagnis, C.; Dagorn, J. C.; Iovanna, J. L. p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. EMBO Rep. 2002, 3, 165-170.
15. Mohammad, H. P.; Seachrist, D. D.; Quirk, C. C.; Nilson, J. H. Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone. Mol. Endocrinol. 2004, 18, 2583-2593.
16. Jiang, W. G.; Watkins, G.; Douglas-Jones, A.; Mokbel, K.; Mansel, R. E.; Fodstad, O. Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status. Int. J. Cancer 2005, 117, 730-737.
17. Malicet, C.; Lesavre, N.; Vasseur, S.; Iovanna, J. L. p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth. Mol. Cancer 2003, 2, 37.
18. Vasseur, S.; Hoffmeister, A.; Garcia-Montero, A.; Mallo, G. V.; Feil, R.; Kuhbandner, S.; Dagorn, J. C.; Iovanna, J. L. p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis. Oncogene 2002, 21, 1685-1694.
19. Bratland, A.; Risberg, K.; Maelandsmo, G. M.; Gutzkow, K. B.; Olsen, O. E.; Moghaddam, A.; Wang, M. Y.; Hansen, C. M.; Blomhoff, H. K.; Berg, J. P.; Fodstad, O.; Ree, A. H. Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer Res. 2000, 60, 5578-5583.
20. Santner, S.; Dawson, P. J.; Tait, L.; Soule, H. D.; Eliason, J.; Mohamed, A. N.; Wolman, S. R.; Heppner, G. H.; Miller, F. R. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 2001, 652, 101-110.
21. Sadowski, H. B.; Gilman, M. Z. Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 1993, 362, 79-83.
22. Thukral, S. K.; Lu, Y.; Blain, G. C.; Harvey, T. S.; Jacobsen, V. L. Discrimination of DNA binding sites by mutant p53 proteins. Mol. Cell Biol. 1995, 15, 5196-5202.
23. Lee, C. W.; Sorensen, T. S.; Shikama, N.; La Thangue, N. B. Functional interplay between p53 and E2F through co-activator p300. Oncogene 1998, 16, 2695-2710.
24. Iyer, N. G.; Chin, S. F.; Ozdag, H.; Daigo, Y.; Hu, D. E.; Cariati, M.; Brindle, K.; Aparicio, S.; Caldas, C. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl. Acad. Sci. USA 2004, 101, 7386-7391.
25. Okorokov, A. L.; Ponchel, F.; Milner, J. Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J. 1997, 16, 6008-6017.
26. Pilat, M. J.; Christman, J. K.; Brooks, S. C. Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res. Treat. 1996, 37, 253-266.
27. Vasseur, S.; Vidal Mallo, G.; Fiedler, F.; Bodeker, H.; Canepa, E.; Moreno, S.; Iovanna, J. L. Cloning and expression of the human p8, a nuclear protein with mitogenic activity. Eur. J. Biochem. 1999, 259, 670-675.
28. Carracedo, A.; Egia, A.; Guzman, M.; Velasco, G. p8 Upregulation sensitizes astrocytes to oxidative stress. FEBS Lett. 2006, 580, 1571-1575.
29. Jiang, W. G.; Davies, G.; Martin, T. A.; Kynaston, H.; Mason, M. D.; Fodstad, O. Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int. J. Mol. Med. 2006, 18, 981-986.
30. Upadhyay, S.; Li, G.; Liu, H.; Chen, Y. Q.; Sarkar, F. H.; Kim, H. R. bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res. 1995, 55, 4520-4524.
31. Kolli, S.; Buchmann, A. M.; Williams, J.; Weitzman, S.; Thimmapaya, B. Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC. Proc. Natl. Acad. Sci. USA 2001, 98, 4646-4651.
32. Path, G.; Opel, A.; Knoll, A.; Seufert, J. Nuclear protein p8 is associated with glucose-induced pancreatic beta-cell growth. Diabetes 2004, 53(Suppl. 1), S82-S85.
33. Ball, K. L. p21: structure and functions associated with cyclin-CDK binding. Prog. Cell Cycle Res. 1997, 3, 125-134.
34. Koff, A.; Giordano, A.; Desai, D.; Yamashita, K.; Harper, J. W.; Elledge, S.; Nishimoto, T.; Morgan, D. O.; Franza, B. R.; Roberts, J. M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992, 257, 1689-1694.
35. Garnovskaya, M. N.; Mukhin, Y. V.; Vlasova, T. M.; Grewal, J. S.; Ullian, M. E.; Tholanikunnel, B. G.; Raymond, J. R. Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation. J. Biol. Chem. 2004, 279, 24899-24905.
36. Zarkowska, T.; Mittnacht, S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 1997, 272, 12738-12746.
37. Knudsen, E. S.; Wang, J. Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 1996, 271, 8313-8320.
38. Welch, P. J.; Wang, J. Y. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 1993, 75, 779-790.
39. Dulic, V.; Stein, G. H.; Far, D. F.; Reed, S. I. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell Biol. 1998, 18, 546-557.
40. Medema, R. H.; Klompmaker, R.; Smits, V. A.; Rijksen, G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998, 16, 431-441.
41. Niculescu, A. B., 3rd; Chen, X.; Smeets, M.; Hengst, L.; Prives, C.; Reed, S. I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell Biol. 1998, 18, 629-643.
42. Smits, V. A.; Medema, R. H. Checking out the G(2)/M transition. Biochim. Biophys. Acta 2001, 1519, 1-12.
43. Waldman, T.; Kinzler, K. W.; Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55, 5187-5190.
44. Waldman, T.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996, 381, 713-716.
45. Staversky, R. J.; Vitiello, P. F.; Gehen, S. C.; Helt, C. E.; Rahman, A.; Keng, P. C.; O'Reilly, M. A. p21(Cip1/Waf1/Sdi1) protects against hyperoxia by maintaining expression of Bcl-X(L). Free Radic. Biol. Med. 2006, 41, 601-609.
46. Tian, H.; Wittmack, E. K.; Jorgensen, T. J. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 2000, 60, 679-684.
47. Zhang, Y.; Fujita, N.; Tsuruo, T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999, 18, 1131-1138.
48. Vitiello, P. F.; Staversky, R. J.; Gehen, S. C.; Johnston, C. J.; Finkelstein, J. N.; Wright, T. W.; O'Reilly, M. A. p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth. Am. J. Pathol. 2006, 168, 1838-1847.
49. Schmidt, M.; Lu, Y.; Liu, B.; Fang, M.; Mendelsohn, J.; Fan, Z. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene 2000, 19, 2423-2429.
50. Wang, Z.; Goulet, R., 3rd; Stanton, K. J.; Sadaria, M.; Nakshatri, H. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005, 25, 2367-2379.
51. Shoemaker, A. R.; Oleksijew, A.; Bauch, J.; Belli, B. A.; Borre, T.; Bruncko, M.; Deckwirth, T.; Frost, D. J.; Jarvis, K.; Joseph, M. K.; Marsh, K.; McClellan, W.; Nellans, H.; Ng, S.; Nimmer, P.; O'Connor J, M.; Oltersdorf, T.; Qing, W.; Shen, W.; Stavropoulos, J.; Tahir, S. K.; Wang, B.; Warner, R.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo. Cancer Res. 2006, 66, 8731-8739.